Mutants of replication competent vaccinia virus
OwnerBertram Jacobsinventor
Life of this patent
Estimating the term…
Loading patent…
OwnerBertram Jacobsinventor
Estimating the term…
The present invention relates to vaccines having an increased level of safety comprising recombinant vaccinia viruses. The invention also relates to methods for stimulating a protective immune response in an immunized host using the vaccines of the invention. The vaccines and recombinant vaccinia viruses of the invention comprise a first nucleic acid comprising an expression control sequence and a second nucleic acid comprising an exogenous nucleic acid encoding a conditional replication gene product, wherein the expression control sequence is operably linked to the exogenous nucleic acid. The exogenous nucleic acid may, by its expression or non-expression, confer upon the recombinant vaccinia virus either sensitivity or dependence upon an exogenous molecule (e.g. a drug) or a condition. Importantly, to allow the recombinant vaccinia viruses of the invention to replicate normally under permissive conditions, the exogenous nucleic acid is inserted into a non-essential locus, e.g., the E2L/E3L inter-genic locus, K1L/K2L inter-genic locus, the superoxide dismutate locus, and the 7.5 K locus.
A recombinant vaccinia virus comprising:
A recombinant vaccinia virus comprising:
A recombinant vaccinia virus comprising:
A recombinant vaccinia virus comprising:
A recombinant vaccinia virus comprising:
A recombinant vaccinia virus comprising:
A recombinant vaccinia virus comprising:
A recombinant vaccinia virus comprising:
Dependencies are inferred from the claim text.